Ted White is CEO & President at Verrica Pharmaceuticals Inc. (VRCA). They have made 11 open-market trades across 1 company since 2018, most recently 2024-08-27.
CIK 0001741964
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $351K since 2018, against 4 sales. Across 7 scored buys the stock is down 5.3% at ninety days, and 5.3 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| VRCA | 215,967 | $762K |
Shares reported on the most recent Form 4, priced at the 2024-08-28 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 86% | 57% | 43% |
| Avg Move | +7.0% | +0.0% | -5.3% |
| Alpha | +5.5% | -2.4% | -5.3% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRCA | SELL | 2024-08-26 | 2024-08-28 | $2.63 | $155K | -16.3% | -27.5% | -52.4% |
| VRCA | SELL | 2024-07-22 | 2024-07-23 | $7.06 | $460K | -20.5% | -61.8% | -78.5% |
| VRCA | SELL | 2023-11-14 | 2023-11-16 | $2.94 | $164K | +12.7% | +60.2% | +52.2% |
| VRCA | SELL | 2023-07-24 | 2023-07-25 | $4.83 | $490K | -2.4% | -19.0% | -34.2% |
| VRCA | BUY | 2022-07-05 | 2022-07-05 | $2.10 | $50K | +22.1% | +20.5% | +13.7% |
| VRCA | BUY | 2022-07-05 | 2023-02-21 | $2.10 | $16K | -14.7% | -26.5% | -31.8% |
| VRCA | BUY | 2021-06-04 | 2021-06-07 | $9.95 | $40K | +12.8% | -2.2% | +22.1% |
| VRCA | BUY | 2020-08-13 | 2020-08-17 | $6.28 | $134K | +9.3% | +10.5% | +4.4% |
| VRCA | BUY | 2018-08-20 | 2018-08-21 | $16.36 | $5K | +2.8% | -3.7% | -22.5% |
| VRCA | BUY | 2018-08-14 | 2018-08-16 | $15.69 | $39K | +10.7% | +0.9% | -16.3% |
| VRCA | BUY | 2018-06-19 | 2018-08-15 | $15.00 | $68K | +6.3% | +0.6% | -6.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.